

## Recent advances in the perioperative management of preeclampsia

An Essay
Submitted for partial fulfillment of Master Degree in
Anesthesiology
Presented by

## Yahya Shaker Abd Elsalam Gewely

M.B.B.Ch. Faculty of Medicine – Alexandria University

**Under Supervision of** 

## Professor Doctor/ Elham Abd El-latif Syam

Professor of Anesthesiology, Intensive Care & Pain Management Faculty of Medicine – Ain Shams University

## **Professor Doctor/ Reem Hamdy Elkabarity**

Professor of Anesthesiology, Intensive Care & Pain Management Faculty of Medicine - Ain Shams University

## **Doctor/Wael Abd Elmoneim Mohammed**

Lecturer of Anesthesiology, Intensive Care & Pain Management Faculty of Medicine - Ain Shams University

> Faculty of Medicine Ain Shams University 2017



#### Acknowledgment

First and foremost, I relate any success to ALLAH, the most graceful, the creator of all these reasons which I used to finish this work, and his messenger Prophet Mohamed (peace and prayers) the greatest teacher and guide of all times.

I cannot express my deepest gratitude and respect to Professor Doctor/ Elham Abd El-latif Syam,

Professor of Anesthesiology, Intensive Care & Pain Management, Faculty of Medicine, Ain Shams University, for her support and encouragement throughout the accomplishment of this study.

Words cannot be enough to express my deepest thanks

and gratitude to Professor Doctor/Reem Hamdy

Elkabarity, professor of Anesthesiology, Intensive Care & Pain Management, Faculty of Medicine.

Ain Shams University, for her devoted revision and continuous correction for this humble study.

Last but not least, my deepest appreciation for Doctor/Wael Abd Elmoneim Mohammed.

Lecturer of Anesthesiology, Intensive Care & Pain Management, Faculty of Medicine, Ain Shams University, for his time, effort and continuous help to make me capable of finishing this study.

Finally, I dedicate all this to my family, my parents and my wife who cared, bared and pushed me forward to finish and make all this come true.

Yahya Shaker Abd Elsalam Gewely

# List of Contents

Title	Page No.
Introduction	i
Aim of the Work	3
Chapter 1: Pathophysiology of preeclampsia	a4
Chapter 2: Management of Preeclampsia	36
Chapter 3: Recent advances in PET Managr	ment 86
References	
Arabic summary	
List of Tables	
List of Tables cont	Error! Bookmark not defined.
List of Abbreviations	Error! Bookmark not defined.

# List of Tables

Table No.	Title	Page No.
Table (1): Tennessee a	and Mississipi classifica	ation of Hellp syndrome.
Table (2): Timing of d	elivery and gestation of	f presentation of
preeclampsia		$\dots \dots $
Table (3): Indications	od delivery in preeclam	ntic patients 49
Table (4): Guidelines	for selecting antihypert	ensive therapy 54
Table (5): Manifestati	ons of preeclampsia	67
Table (6): Ongoing in	vestigations in hyperter	nsive pregnant females.
Table (7): MG sulphar	te regeime	103

# List of Abbreviations

Abb.	Full term
ACR	Albumin Creatinine Ratio
AFLP	Acute Fatty Liver of Pregnancy
AOR	Adjusted Odds Ratio
ARDS	Acute Respiratory Distress Syndrome
ASA	American society of Anesthesiologist
BMI	Basal Metabolic Rate
BP	Blood Presure
C.S	Cesareans Section
CNS	Central Nervous System
CO	Cardiac Output
CSE	Combined Spinal Epidural
CST	Corticosteroids
CVC	Central venous catheter
CVP	Central venous Pressure
CVS	Cardiovascular System
DBP	Diastolic Blood Pressure
DIC	Disseminated Intravenous Coagulopathy
DM	Diabetes Mellitus
FFP	Fresh Frozen Plasma
FGR	Fetal Growth Retardation
GA	General Anesthesia

HCS	HCG	Human Chorionic Gonadotropin
HTN. Hypertension HUS. Hemolytic Uremic Syndrome IHD. Ischemic Heart Disease IUGR. Intra Uterine Growth Retardation IV. Intravenous LFT. liver Function Tests LMWH. Low Molecular Weight Heparin MHC. Major Histocompatibility NICU. Neonatal Intensive Care Unit NK. Natural Killer NPV. Negative Predictive Value NSAIDs. Non-Steroidal Anti-inflammatory P1GF. Placental Growth Factor PAP. Pulmonary Artery Pressure PCWP. Pulmonary Capillary Wedge pressure PET. Preeclampsia SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE. Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura	HCS	Human Chorionic Somatomammotropin
HUS. Hemolytic Uremic Syndrome IHD. Ischemic Heart Disease IUGR. Intra Uterine Growth Retardation IV. Intravenous LFT. liver Function Tests LMWH. Low Molecular Weight Heparin MHC. Major Histocompatibility NICU. Neonatal Intensive Care Unit NK. Natural Killer NPV. Negative Predictive Value NSAIDs. Non-Steroidal Anti-inflammatory P1GF. Placental Growth Factor PAP Pulmonary Artery Pressure PCWP. Pulmonary Capillary Wedge pressure PET. Preeclampsia SBP Systolic blood Pressure sEng. Soluble Endoglublin SGA Small for Gestational Age SLE Systemic Lupus Erythematosus SVR Systemic Venous Return TTP Thrombocytopenic Purpura	HLA	Human Leukocyte Antigen
IHDIschemic Heart DiseaseIUGRIntra Uterine Growth RetardationIVIntravenousLFTliver Function TestsLMWHLow Molecular Weight HeparinMHCMajor HistocompatibilityNICUNeonatal Intensive Care UnitNKNatural KillerNPVNegative Predictive ValueNSAIDsNon-Steroidal Anti-inflammatoryP1GFPlacental Growth FactorPAPPulmonary Artery PressurePCWPPulmonary Capillary Wedge pressurePETPreeclampsiaSBPSystolic blood PressuresEngSoluble EndoglublinSGASmall for Gestational AgeSLESystemic Lupus ErythematosusSVRSystemic Venous ReturnTTPThrombocytopenic Purpura	HTN	Hypertension
IUGR		
IV	IHD	Ischemic Heart Disease
LFT	IUGR	Intra Uterine Growth Retardation
LMWH. Low Molecular Weight Heparin MHC. Major Histocompatibility NICU. Neonatal Intensive Care Unit NK. Natural Killer NPV. Negative Predictive Value NSAIDs. Non-Steroidal Anti-inflammatory P1GF. Placental Growth Factor PAP. Pulmonary Artery Pressure PCWP. Pulmonary Capillary Wedge pressure PET. Preeclampsia SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE. Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura	IV	Intravenous
MHC	LFT	liver Function Tests
NICU	LMWH	Low Molecular Weight Heparin
NK. Natural Killer NPV. Negative Predictive Value NSAIDs. Non-Steroidal Anti-inflammatory P1GF. Placental Growth Factor PAP. Pulmonary Artery Pressure PCWP. Pulmonary Capillary Wedge pressure PET. Preeclampsia SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura	MHC	Major Histocompatibility
NPV	NICU	Neonatal Intensive Care Unit
NSAIDs	NK	Natural Killer
P1GF. Placental Growth Factor PAP. Pulmonary Artery Pressure PCWP. Pulmonary Capillary Wedge pressure PET. Preeclampsia SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE. Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura	NPV	Negative Predictive Value
PAP. Pulmonary Artery Pressure PCWP. Pulmonary Capillary Wedge pressure PET. Preeclampsia SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE. Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura	NSAIDs	Non-Steroidal Anti-inflammatory
PCWP. Pulmonary Capillary Wedge pressure PET. Preeclampsia SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE. Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura	P1GF	Placental Growth Factor
PET. Preeclampsia SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE. Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura		v v
SBP. Systolic blood Pressure sEng. Soluble Endoglublin SGA. Small for Gestational Age SLE. Systemic Lupus Erythematosus SVR. Systemic Venous Return TTP. Thrombocytopenic Purpura	PCWP	Pulmonary Capillary Wedge pressure
sEng	PET	Preeclampsia
SGA	SBP	Systolic blood Pressure
SLESystemic Lupus Erythematosus SVRSystemic Venous Return TTPThrombocytopenic Purpura	sEng	Soluble Endoglublin
SVRSystemic Venous Return TTPThrombocytopenic Purpura	SGA	Small for Gestational Age
TTPThrombocytopenic Purpura	SLE	Systemic Lupus Erythematosus
		·
UOUrinary Output	TTP	Thrombocytopenic Purpura
• •	UO	Urinary Output

US	Ultrasound
MRI	Magnetic Resonance Imaging
UTI	Urinary Tract Infection
VEGFVascu	lar Endothelial Growth Factor
VTE	Venous Thromboembolism

## Introduction

Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum. It is clinically defined by hypertension and proteinuria, with or without pathologic edema (Vatten and Skjaerven, 2004).

Recent investigations are being of greater help nowadays. Congo red spotting test (urine CR) may be better than currently used current dipstick methods at diagnosing preeclampsia and indicating the need for medically indicated delivery, other investigations as measuring albumin urinary by using performance liquid chromatography in early and uncomplicated pregnancy, spot urinary albumin: creatinine ratio (ACR) values are higher. If measured early in the second trimester, an ACR of 35.5 mg/mmol or higher may predict preeclampsia before symptoms arise (Buhimschi et al., 2014).

Complications of preeclampsia are serious and may affect both the mother and the fetus: preeclampsia can be complicated by different types of stroke either ischemic or hemorrhagic which may lead intercerebral hemorrhage. Other serious to complication is HELLP syndrome. Recently, this syndrome undergoes new classification made by university of Mississippi, which classified the disease classes according to degree 3 into

thrombocytopenia, evidence of suggestive hemolysis and evidence of hepatic dysfunction, classification made by university of Tennessee, which had the same criteria (Martin et al., 2006).

Adequate new evidence of reducing the risk of preeclampsia, preterm birth, and IUGR in women at increased risk for preeclampsia, who received lowdose aspirin, has demonstrated substantial benefit. Low-dose aspirin (range, 60 to 150 mg/d) reduced the risk for preeclampsia by 24% in clinical trials and reduced the risk for preterm birth by 14% and IUGR by 20% (Michael, 2014).

The usage of antihypertensive drugs in mild pregnancy-induced hypertension or pre-eclampsia is not strongly recommended, only when blood pressure is greater than 150/100 mmHg, labetalol, methyldopa or nifedipine are advised as the drugs of choice. Despite that the conventional treatment of pregnancy induced hypertension is Methyldopa (Aldomet), new studies revealed that Beta blockers and calcium channel blockers seem to be more effective than Methyldopa as they reduce the overall risk of developing proteinuria/pre-eclampsia when either are compared with Methyldopa (Abalos et al., 2014).

## AIM OF THE WORK

Discussing recent anesthetic management for preeclampsia and other hypertensive disorders, and to emphasize on the importance of the peri-operative management to prevent further complications so we can improve prognosis.

## PATHOPHYSIOLOGY OF PRE-**ECLAMPSIA**

## **Definitions:**

Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum. It is defined as increased blood pressure and proteinuria, with pathologic edema or without it (Sibai, 2003).

A definite medical consensus is lacking regarding defining preeclampsia and determining its values, but there're reasonable criteria for women who have normal blood pressure before 20 weeks' gestation, this criteria is associated with measuring the patient's blood pressure, 2 successive consecutive measurements with 4-6 hours interval are needed and the results are 140/90 or more. Preeclampsia in a patient with preexisting essential hypertension is diagnosed if systolic blood pressure has increased by 30 mm Hg or if diastolic blood pressure has increased by 15 mm Hg (Vatten and Skjaerven, 2004).

Eclampsia is defined as seizures without any attributable other cause in a patient with preeclampsia (Ngoc et al., 2006).

The international incidence of the disease is 5-14%, while this incidence increases in the developing countries as it reaches 4-18% (Sibai, 2004).

Hypertensive disorders of pregnancy are considered one of the commonest causes (the second) of stillbirth and early neonatal deaths (Ness and Roberts, 1996).

Despite hypertension is a firm characteristic of preeclampsia, other symptoms or laboratory findings appear first, as edema, headache, visual disturbances, and epigastric tenderness (Tuffnell et al., 2006).

#### **Classification:**

The proper classification of any disease is supposed reflection of multiple factors pathophysiology, risks outcome. and Numerous prestigious bodies have accepted our following classification of hypertensive disorders whether proteinuria is required or not to diagnose preeclampsia (Magee et al., 2014).

Internationally, in the latest guidelines, proteinuria is not required anymore to diagnose pre-eclampsia, leaving only the British NICE guideline with this requirement (Tranquilli et al., 2013).

#### The classification is as follows:

- 1- Pre-eclampsia Eclampsia.
- 2- Gestational hypertension.
- 3- Chronic hypertension: a- Essential. b- Secondary.
- c- White coat: it means only elevation of the BP while measured by a clinician; otherwise it is normal if measured by home BP monitoring for example (Bulletin, 2002).

### o Pre-eclampsia:

It is a multisystem disorder related only to human pregnancy characterized by hypertension (HTN) and involvement of one or more other organ systems and/or the baby. Despite proteinuria is the commonest additional feature next to HTN and easily recognised, it shouldn't be considered as a clinical obligation for the diagnosis. Pre-existing HTN is a strong risk factor for developing PET (Nelson, 2003).

Preeclampsia is classified into mild and severe, mild preeclampsia is defined as increased blood pressure (BP  $\geq$ 140/90 mm Hg) on 2 successive consecutive measurements, at least 6 hours apart, with excluding end-organ damage, in a patient who had normal BP before 20 weeks' gestation. In a patient with preexisting essential HTN, preeclampsia is diagnosed if systolic blood pressure (SBP) has increased by 30 mm Hg or if diastolic blood pressure (DBP) has increased by 15 mm Hg (Villar et al., 2001).

While severe preeclampsia doesn't have simple definition, it has a criterion to be fulfilled. This criterion is present preeclampsia with 1 of the following symptoms or signs:

- Measurements of 160 mm Hg or greater for her systolic or 110 mm Hg for her diastolic blood pressure on 2 successive consecutive measurements, at least 6 hours apart.
- Reduced oxygen saturation that leads to cyanosis or pulmonary edema.
- Low urine output (24 hour collection of less than 400 mL).
- Investigations that reveal either impaired liver functions or proteinuria of more than 500 mg in a 24 hour collection. If the urine sample is random, at least 2 samples with 4 hours interval is needed with proteinuria of 3+ or higher
- Persistent headache.
- Oligohydramnios decreased fetal growth, or placental abruption.
- Upper right quadrant or epigastric pain.
- Decreased platelet count.

Severe preeclampsia may complicate disseminated intravascular coagulopathy (DIC), renal and liver failure or even central nervous system (CNS)



disorders or even HELLP syndrome (Khedun et al., 1997).

Preeclampsia is mild in 75% of cases and severe in 25% of them. If seizures develop on top, the disorder has developed into eclampsia (Sibai, 2004).

### Superimposed pre-eclampsia:

If a chronic hypertension patient develops further manifestation of preeclampsia after 20 weeks of gestation, in this case it's diagnosed as superimposed preeclampsia. If proteinuria preceded other manifestations it's harder to diagnose the disease as proteinuria normally increases during pregnancy. In these patients closer monitoring is required, but the diagnosis is not confirmed without appearance of other maternal systemic manifestations or fetal effects with or without Small for Gestational Age (SGA), as oligohydramnios or abnormal flow in uterine artery Doppler (Chappell et al., 2008).

Preeclampsia as previously defined could diagnosed when hypertension appears after 20 weeks of gestation, with the involvement of one or more of the following: (Ritchie and Brown, 2010).